





Medical Research Commercialisation

Medical Research Future Fund
Snapshot 2019–20 to 2020–21



Theme
Research translation



Goal

To support early-stage health and medical research and innovation in Australia through to proof-of-concept and beyond, providing opportunities for commercialisation



Budget

\$311.3 million

over 10 years

Total Budget allocation from 2018–19 (as at Budget 2019–20)

Total committed = \$67.3 million (for 2017–18 to 2021–22)

Grant rounds in progress = Nil from the Australian Government, but applications for BioMedTech Horizons Round 3 are administered by MTPConnect and open until 16 December 2019


Not yet allocated = \$254.0 million

	2019–20 (\$m)	2020–21 (\$m)	2021–22 (\$m)	2022–23 (\$m)
Budget	15.3	35.3	35.3	35.0
Committed	15.3	25.3	1.3	-
Grant rounds in progress	-	-	-	-
Not yet allocated	0.0	10.0	34.0	35.0

Funding timeline

BioMedTech Horizons

Biomedical Translation Bridge



See [MTPConnect](#) for specific grant dates

Grant processes: Open and competitive

MTPConnect is the lead entity for the BioMedTech Horizons and the Biomedical Translation Bridge initiatives. Applications for funding under these initiatives will be selected by MTPConnect.

Early funding priorities

- BioMedTech Horizons round 1 priority areas: precision medicine and 3D anatomical printing
- BioMedTech Horizons round 2 priority areas: cardiovascular, orthopaedics, emergency medicine/trauma and ophthalmology
- BioMedTech Horizons round 3 priority areas:
 - digitally enabled medical devices in mobile health, health information technology, wearable devices, telehealth and telemedicine, and digitally enabled personalised medicine
 - implantable digitally enabled medical devices addressing unmet needs in any therapeutic area
 - general medical devices in the areas of regenerative medicine, women's health, cardiovascular, orthopaedics, neuroscience, general surgery and oncology

Current or completed activity

- 11 projects funded under BioMedTech Horizons Round 1. Round 2 closed and under assessment. Round 3 open for applications, closing 16 December 2019
- Biomedical Translation Bridge Round 1 closed and under assessment



Delivery horizons

Establish 0 to 1 years

- Establish commercialisation initiatives, including BioMedTech Horizons and Biomedical Translation Bridge

Expand 1 to 3 years

- Assess the first initiatives
- Refine initiatives or establish new ones to increase the number and effectiveness of commercialisation investments

Embed 4 to 10 years

- Embed MRFF-funded pathways for investing in ideas and innovations to increase commercialisation opportunities and improve patient outcomes

Measures of success

- _____
New health technologies and treatments are developed and trialled
- _____
Increased commercialisation of health research outcomes
- _____
Research community has greater capacity and capability to undertake translational research